Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 8602
TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM294112(US9585881, Example 99 | methyl [4-(2-{(2S,4S)-1-[(...)
Affinity DataIC50: 1.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 2.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US9394250, 98 | US9585881, Example 98 | US10336741...)
Affinity DataIC50: 2.30nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US9394250, 20 | US9585881, Example 20 | US10336741...)
Affinity DataIC50: 3.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50: 4.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238260(US9394250, 73 | US9585881, Example 73 | US10336741...)
Affinity DataIC50: 4.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US9394250, 88 | US9585881, Example 88 | US10336741...)
Affinity DataIC50: 5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US9394250, 94 | US9585881, Example 94 | US10336741...)
Affinity DataIC50: 5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238261(US9394250, 79 | US9585881, Example 79 | US10336741...)
Affinity DataIC50: 6.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US9394250, 98 | US9585881, Example 98 | US10336741...)
Affinity DataIC50: 7.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238269(US9394250, 111 | US10336741, Example 111 | US10882...)
Affinity DataIC50: 8.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM294104(US9585881, Example 86 | methyl [4-(2-{(2S,4R)-1-({...)
Affinity DataIC50: 9.90nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238255(US9394250, 43 | US9585881, Example 43 | US10336741...)
Affinity DataIC50: 11nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238253(US9394250, 37 | US9585881, Example 37 | US10336741...)
Affinity DataIC50: 13nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US9394250, 55 | US9585881, Example 55 | US10336741...)
Affinity DataIC50: 14nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US9394250, 9 | US9585881, Example 9 | US10336741, ...)
Affinity DataIC50: 17nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US9394250, 93 | US9585881, Example 93 | US10336741...)
Affinity DataIC50: 18nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US9394250, 57 | US9585881, Example 57 | US10336741...)
Affinity DataIC50: 27nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50: 78nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US9394250, 94 | US9585881, Example 94 | US10336741...)
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US9394250, 94 | US9585881, Example 94 | US10336741...)
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238260(US9394250, 73 | US9585881, Example 73 | US10336741...)
Affinity DataIC50: 3.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238261(US9394250, 79 | US9585881, Example 79 | US10336741...)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US9394250, 88 | US9585881, Example 88 | US10336741...)
Affinity DataIC50: 5.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM294112(US9585881, Example 99 | methyl [4-(2-{(2S,4S)-1-[(...)
Affinity DataIC50: 8.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 9.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US9394250, 98 | US9585881, Example 98 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US9394250, 98 | US9585881, Example 98 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US9394250, 93 | US9585881, Example 93 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US9394250, 71 | US9585881, Example 71 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US9394250, 93 | US9585881, Example 93 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM294112(US9585881, Example 99 | methyl [4-(2-{(2S,4S)-1-[(...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238269(US9394250, 111 | US10336741, Example 111 | US10882...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US9394250, 55 | US9585881, Example 55 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US9394250, 9 | US9585881, Example 9 | US10336741, ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US9394250, 9 | US9585881, Example 9 | US10336741, ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US9394250, 20 | US9585881, Example 20 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US9394250, 20 | US9585881, Example 20 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238253(US9394250, 37 | US9585881, Example 37 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238253(US9394250, 37 | US9585881, Example 37 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238255(US9394250, 43 | US9585881, Example 43 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238255(US9394250, 43 | US9585881, Example 43 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US9394250, 88 | US9585881, Example 88 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US9394250, 55 | US9585881, Example 55 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetProthrombin(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US9394250, 57 | US9585881, Example 57 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US9394250, 57 | US9585881, Example 57 | US10336741...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: